How are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)
How are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)
复制标题
DOI：
10.1007/s10096-020-04031-2
复制
发表时间：
2020-09-09
影响因子：
4.5
通讯作者：
Saeed, Kordo
中科院分区：
文献类型：
--
作者：
Poole, Stephen;Townsend, Jennifer;Saeed, Kordo
新的快速诊断测试(RDT)为优化临床护理和改善患者预后提供了巨大的潜力。在这项研究中，我们旨在评估世界各地目前的使用模式，确定成功实施的问题，并就如何引入新测试提出最佳实践建议。国际抗菌化疗学会(ISAC)快速诊断和生物标记物工作组设计了一项电子调查，重点是世界各地RDT的可用性、结构和影响。该文件于2019年12月分发给国际会计准则委员会成员。根据联合国人类发展指数(HDI)对结果进行整理。调查收集了来自31个不同国家的81份回复。84%的机构报告可全天候提供任何检测。在较发达的国家，这更多是针对呼吸道病毒，而在高、中/低发达国家，这是针对艾滋病毒和病毒性肝炎的。在那些进行快速测试的人中，只有37%的人测量了影响。RDTs不存在‘一刀切’的解决方案：要求必须针对部署RDT的医疗保健环境量身定做，在此之前应该考虑许多因素。
Novel rapid diagnostic tests (RDTs) offer huge potential to optimise clinical care and improve patient outcomes. In this study, we aim to assess the current patterns of use around the world, identify issues for successful implementation and suggest best practice advice on how to introduce new tests. An electronic survey was devised by the International Society of Antimicrobial Chemotherapy (ISAC) Rapid Diagnostics and Biomarkers working group focussing on the availability, structure and impact of RDTs around the world. It was circulated to ISAC members in December 2019. Results were collated according to the UN human development index (HDI). 81 responses were gathered from 31 different countries. 84% of institutions reported the availability of any test 24/7. In more developed countries, this was more for respiratory viruses, whereas in high and medium/low developed countries, it was for HIV and viral hepatitis. Only 37% of those carrying out rapid tests measured the impact. There is no 'one-size fits all' solution to RDTs: the requirements must be tailored to the healthcare setting in which they are deployed and there are many factors that should be considered prior to this.